BACKGROUND: Lymphoblastic lymphoma (LBL) is a highly aggressive lymphoma, for which intensive chemotherapy is necessary. This study was designed to evaluate the efficacy and toxicity of a modified acute lymphoblastic leukemia (ALL)-Berlin-Frankfurt-Münster (BFM)-90-based protocol in Chinese children and adolescents with LBL. METHODS: From March 1998 to November 2006, 60 untreated patients with LBL (age <18 years) from a single institution were enrolled. All patients were treated with the modified ALL-BFM-90 protocol, and prophylactic cranial radiotherapy was omitted. RESULTS: The median age of the patients was 10 years (range, 2.5-18 years). Forty-eight (80%) patients had T-cell LBL, and 59 (98.3%) of the patients were stage III/IV. At the end of induction remission Ia (day 33), 3 patients had died of treatment-related toxicity. In the remaining 57 patients, complete remission (CR) or CR undetermined (CRu) had occurred in 47 (82.45%), who were designated as the moderate-risk group and partial remission (PR) had occurred in 10 patients (17.54%), who were designated the high-risk group. All patients experienced grade 3-4 hematological toxicity. At a median follow-up of 35 months, event-free survival was 78.81%+/-0.05 for all patients; the figure was 88.34%+/-0.05 for the moderate-risk group (90.91%+/-0.08 for stage III, 87.68%+/-0.06 for stage IV, 100% for those with B-cell LBL, 84.78%+/-0.06 for those with T-cell LBL, and 82.94%+/-0.08 for stage IV patients with more than 25% blast cells in bone marrow [BM]). The event-free survival in the high-risk group was 60%+/-0.15. CONCLUSION: This modified ALL-BFM-90 protocol is an effective regimen and it greatly improved the survival rate of Chinese children and adolescents with LBL compared with the ALL protocols used previously.
BACKGROUND:Lymphoblastic lymphoma (LBL) is a highly aggressive lymphoma, for which intensive chemotherapy is necessary. This study was designed to evaluate the efficacy and toxicity of a modified acute lymphoblastic leukemia (ALL)-Berlin-Frankfurt-Münster (BFM)-90-based protocol in Chinese children and adolescents with LBL. METHODS: From March 1998 to November 2006, 60 untreated patients with LBL (age <18 years) from a single institution were enrolled. All patients were treated with the modified ALL-BFM-90 protocol, and prophylactic cranial radiotherapy was omitted. RESULTS: The median age of the patients was 10 years (range, 2.5-18 years). Forty-eight (80%) patients had T-cell LBL, and 59 (98.3%) of the patients were stage III/IV. At the end of induction remission Ia (day 33), 3 patients had died of treatment-related toxicity. In the remaining 57 patients, complete remission (CR) or CR undetermined (CRu) had occurred in 47 (82.45%), who were designated as the moderate-risk group and partial remission (PR) had occurred in 10 patients (17.54%), who were designated the high-risk group. All patients experienced grade 3-4 hematological toxicity. At a median follow-up of 35 months, event-free survival was 78.81%+/-0.05 for all patients; the figure was 88.34%+/-0.05 for the moderate-risk group (90.91%+/-0.08 for stage III, 87.68%+/-0.06 for stage IV, 100% for those with B-cell LBL, 84.78%+/-0.06 for those with T-cell LBL, and 82.94%+/-0.08 for stage IV patients with more than 25% blast cells in bone marrow [BM]). The event-free survival in the high-risk group was 60%+/-0.15. CONCLUSION: This modified ALL-BFM-90 protocol is an effective regimen and it greatly improved the survival rate of Chinese children and adolescents with LBL compared with the ALL protocols used previously.
Authors: A Reiter; M Schrappe; W D Ludwig; M Tiemann; R Parwaresch; M Zimmermann; E Schirg; G Henze; G Schellong; H Gadner; H Riehm Journal: Blood Date: 2000-01-15 Impact factor: 22.113
Authors: M Schrappe; A Reiter; W D Ludwig; J Harbott; M Zimmermann; W Hiddemann; C Niemeyer; G Henze; A Feldges; F Zintl; B Kornhuber; J Ritter; K Welte; H Gadner; H Riehm Journal: Blood Date: 2000-06-01 Impact factor: 22.113
Authors: Birgit Burkhardt; Wilhelm Woessmann; Martin Zimmermann; Udo Kontny; Josef Vormoor; Wolfgang Doerffel; Georg Mann; Guenter Henze; Felix Niggli; Wolf-Dieter Ludwig; Dirk Janssen; Hansjoerg Riehm; Martin Schrappe; Alfred Reiter Journal: J Clin Oncol Date: 2006-01-20 Impact factor: 44.544
Authors: W A Kamps; J P M Bökkerink; F G A J Hakvoort-Cammel; A J P Veerman; R S Weening; E R van Wering; J F van Weerden; J Hermans; R Slater; E van den Berg; W G Kroes; A van der Does-van den Berg Journal: Leukemia Date: 2002-06 Impact factor: 11.528
Authors: Frank G H Hill; Sue Richards; Brenda Gibson; Ian Hann; John Lilleyman; Sally Kinsey; Christopher Mitchell; Christine J Harrison; Osborn B Eden Journal: Br J Haematol Date: 2004-01 Impact factor: 6.998
Authors: Paul C Nathan; Ronnen Maze; Brenda Spiegler; Mark L Greenberg; Sheila Weitzman; Johann K Hitzler Journal: Pediatr Blood Cancer Date: 2004-01 Impact factor: 3.167
Authors: J R Anderson; R D Jenkin; J F Wilson; C R Kjeldsberg; R Sposto; R R Chilcote; P F Coccia; P R Exelby; S Siegel; A T Meadows Journal: J Clin Oncol Date: 1993-06 Impact factor: 44.544
Authors: Robert J Hayashi; Stuart S Winter; Kimberly P Dunsmore; Meenakshi Devidas; Zhiguo Chen; Brent L Wood; Michelle L Hermiston; David T Teachey; Sherrie L Perkins; Rodney R Miles; Elizabeth A Raetz; Mignon L Loh; Naomi J Winick; William L Carroll; Stephen P Hunger; Megan S Lim; Thomas G Gross; Catherine M Bollard Journal: J Clin Oncol Date: 2020-06-17 Impact factor: 44.544